AMS

Business Context and Reporting Period

Company: American Shared Hospital Services (ASHS)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: ASHS provides turn-key technology solutions for stereotactic radiosurgery and advanced radiation therapy. Operations are divided into two segments: Leasing (fee-per-use or revenue-sharing contracts for Gamma Knife and Proton Beam Radiation Therapy equipment) and Retail (direct patient services at owned facilities in the U.S., Peru, Ecuador, and Mexico).
Key Developments: In May 2024, the Company acquired a 60% interest in three Rhode Island radiation therapy centers (the "RI Acquisition"). In July 2024, it began operations at a new LINAC facility in Puebla, Mexico.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 32.9% to $28.3 million, driven primarily by the RI Acquisition and the new Puebla, Mexico facility. Retail segment revenue surged 253% to $12.6 million, while Leasing revenue declined 12.1% to $15.6 million due to contract expirations and lower procedure volumes.
• Profitability: Net income attributable to ASHS increased 258.4% to $2.2 million. This was largely due to a $3.8 million bargain purchase gain from the RI Acquisition, which offset a $3.1 million loss on the write-down of impaired assets (primarily domestic Gamma Knife units).
• Cost Structure: Costs of revenue increased 59.9% to $19.2 million, reflecting higher operating costs associated with the new retail facilities. Depreciation and amortization rose 19.6% due to equipment upgrades and the RI Acquisition.
• Debt: Long-term debt increased significantly as the Company secured two new term loans totaling $9.7 million in 2024 to fund capital expenditures and the RI Acquisition.

Guidance, Outlook, Risks, and Unusual Items

Outlook and Management Commentary

• Expansion: The Company is expanding its retail footprint with a new facility in Guadalajara, Mexico (expected mid-to-late 2025) and plans to construct a Proton Beam Radiation Therapy (PBRT) system in Rhode Island (expected ~36 months) and a LINAC facility in Bristol, Rhode Island (expected 18-24 months).
• Reimbursement: Medicare reimbursement rates for Gamma Knife are projected to increase slightly in 2025 ($7,645 vs. $7,420 in 2024). PBRT rates are also expected to see minor adjustments.
• Liquidity: Management believes current cash ($11.3 million) and a $7.0 million revolving line of credit are sufficient to fund operations and debt obligations for the next 12 months.

Risks and Contingencies

• Internal Controls: The Company identified a material weakness in internal control over financial reporting due to insufficient accounting personnel and resources. Remediation efforts are underway, including hiring a new CFO and accounting staff.
• Debt Covenants: The Company was not in compliance with certain covenants under its DFC Loan (Ecuador operations) as of December 31, 2024, but obtained a waiver in March 2025. Failure to maintain compliance could trigger acceleration of debt.
• Asset Impairment: The Company determined its Gamma Knife portfolio has no remaining salvage value, leading to significant impairment charges. Future impairments are possible as equipment ages.
• Customer Concentration: Two customers accounted for 35% and 27% of total revenue in 2024. Loss of a major customer would materially impact results.
• Regulatory: The Company is not in compliance with SEC Rules 8-04 and 8-05 regarding the RI Acquisition due to the lack of reliable financial data from the acquired entities (formerly in bankruptcy), which limits its ability to raise capital via registration statements.

Investor Verification Checklist

• Verify the Material Weakness Remediation: Confirm the timeline and effectiveness of hiring new accounting staff and implementing new financial reporting controls.
• Assess Debt Covenant Compliance: Monitor the Company's ability to maintain the DFC Loan waivers and meet the Fixed Charge Coverage and Debt-to-EBITDA ratios under the Fifth Third Bank Credit Agreement.
• Review RI Acquisition Integration: Evaluate the actual revenue and profitability of the Rhode Island facilities against the pro forma expectations and the sustainability of the bargain purchase gain.
• Monitor Asset Impairment Trends: Watch for further write-downs on the Gamma Knife portfolio as contracts expire and salvage values remain at zero.
• Check Capital Raising Restrictions: Understand the impact of the SEC Rule 8-04/8-05 non-compliance on the Company's ability to issue new equity or debt.